Skip to main content
Clinical Trials/NCT05124639
NCT05124639
Active, Not Recruiting
N/A

A Pragmatic Randomized Controlled Trial of a Group Self-management Support Program Versus Treatment-as-usual for Anxiety Disorders

Université de Sherbrooke1 site in 1 country414 target enrollmentOctober 6, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Panic Disorder
Sponsor
Université de Sherbrooke
Enrollment
414
Locations
1
Primary Endpoint
Change in Beck Anxiety Inventory (BAI)
Status
Active, Not Recruiting
Last Updated
last year

Overview

Brief Summary

Background. Self-management support is a complementary approach to treatment that aims to educate participants on the nature of anxiety and to improve their strategies to manage symptoms and well-being, thus presenting the potential to enhance recovery, improve outcomes, reduce recurrence rates and lower health care costs. There is limited evidence to support the effectiveness of group self-management support for anxiety disorders in community-based care.

Objectives. This study aims at examining the effectiveness of a virtual group self-management support program (SMS) for anxiety disorders as an add-on to treatment-as-usual (TAU) in community-based care settings. We will also assess the incremental cost/effectiveness ratio and the implementability of the intervention.

Methods. The trial is a pragmatic randomized controlled trial with a pre-treatment, post-treatment (4-month post-randomization), and follow-ups at 8, 12 and 24-months. Intervention. The experimental condition will consist of a 10-week SMS program for anxiety disorders in addition to TAU. The control condition will receive TAU without restrictions for anxiety disorders. Inclusion criteria will comprise being 18 years old or older, French-speaking, and presenting symptoms of anxiety disorders based on self-reported validated assessment scales. Patients will be recruited in the province of Quebec (Canada). Outcome measures: The primary outcome measure is the Beck Anxiety Inventory (BAI). The secondary outcome measures include self-reported instruments for anxiety and depressive symptoms, recovery, self-management, quality of life, and service utilisation. Statistical analysis: Intention-to-treat analysis. A mixed effects regression model will be used to account for between and within-subject variations in the analysis of the longitudinal effects of the intervention.

Expected outcomes. The rigorous evaluation of the SMS intervention in the real world will provide information to decision makers, health care managers, clinicians and patients regarding the added value of group SMS for patients with anxiety disorders. Widespread implementation of this intervention could lead to more efficient mental health care services, to better long-term outcomes and to a significant reduction in the extensive social and economic burden of anxiety disorders.

Registry
clinicaltrials.gov
Start Date
October 6, 2022
End Date
December 21, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • (1) aged 18 and over,
  • (2) fluent in spoken and written French,
  • (3) presence of symptoms of anxiety disorders based on self-reported validated assessment scales and semi-structured assessment interview,
  • (4) access to a computer or tablet connected to the internet with microphone and video camera

Exclusion Criteria

  • (1) previous enrolment in the SMS intervention provided by Relief
  • (2) active suicidal intentions,
  • (3) severe depressive symptoms,
  • (4) active substance-related and addictive disorder,
  • (5) cognitive impairment

Outcomes

Primary Outcomes

Change in Beck Anxiety Inventory (BAI)

Time Frame: Baseline and post-treatment (4-month post-randomization)

Secondary Outcomes

  • Change in Recovery Assessment Scale - Revised(Baseline, post-treatment,12-month and 24-month post-randomization follow-ups)
  • Change in Mental Health Self-Management Questionnaire(Baseline, post-treatment,12-month and 24-month post-randomization follow-ups)
  • Change in Beck Anxiety Inventory(Baseline, post-treatment, and 8-month, 12-month, 24-month post-randomization follow-ups)
  • Change in Generalised Anxiety Disorder-7(Baseline, post-treatment, and 8-month, 12-month, 24-month post-randomization follow-ups)
  • Change in Patient Health Questionnaire-9(Baseline, post-treatment,12-month and 24-month post-randomization follow-ups)
  • Change in Administrative databases records(Starting 12 months prior to participant enrolment up to the 24-month post-randomization follow-up)
  • Change in Assessment of Quality of Life - 6 Dimensions(Baseline, post-treatment, and 8-month, 12-month, 24-month post-randomization follow-ups)
  • Change in Health care use and indirect costs(Baseline, post-treatment, and 8-month, 12-month, 24-month post-randomization follow-ups)

Study Sites (1)

Loading locations...

Similar Trials